SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
Dómine Gómez, Manuel (Hospital Universitario Fundación Jiménez Díaz)
Moran, T. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Martí, J.L. (Hospital General Universitario de Alicante (Alacant, País Valencià))
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau)
Provencio, M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Olmedo, M.E. (Hospital Universitario Ramón y Cajal (Madrid))
Ponce, S. (Hospital 12 de Octubre (Madrid))
Blasco, A. (Consorcio Hospital General Universitario de Valencia. CIBERONC)
Cobo, M. (Hospital Regional Universitario de Málaga)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum-etoposide. In stage IIB-IIIC, the recommended treatment is early concurrent chemotherapy with platinum-etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum-etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum-etoposide is the recommended regimen in patients with sensitive relapse (≥ 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Chemotherapy ; Immunotherapy ; Radiotherapy ; SCLC
Published in:	Clinical & translational oncology, Vol. 22 Núm. 2 (january 2020) , p. 245-255, ISSN 1699-3055

DOI: 10.1007/s12094-020-02295-w
PMID: 32040815

11 p, 824.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles